No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ASRT240621C3000
- 0.08
- +0.06+300.00%
15min DelayClose May 31 09:36 ET
0.08High0.08Low
0.08Open0.02Pre Close15 Volume68 Open Interest3.00Strike Price120.00Turnover401.02%IV209.61%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.2242Delta0.3312Gamma12.44Leverage Ratio-0.0072Theta0.0001Rho2.79Eff Leverage0.0007Vega
Intraday
- 5D
- 1D
News
Assertio Therapeutics' Governance and Shareholder Decisions Update
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Analysts Are Bullish on These Healthcare Stocks: Assertio Therapeutics (ASRT), SurModics (SRDX)
Assertio Names O'Grady CEO
Express News | Assertio Appoints Brendan P. O'Grady, As The Company's New Chief Executive Officer And A Member Of The Board, Effective May 29, 2024
Comments
Investors' belief in the company's poor revenue performance and future decline, not in line with the industry's expected 15% growth, may be causing the low P/S ratio. The current investor sentiment and future expectations are not positive enough to justify a higher P/S ratio.
Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Fly 28% But Investors Aren't Buying For Growth 2
Emany's appointment to Assertio's board is seen as a beneficial step, anticipated to assist in the company's upcoming phase of growth and change. Emany's fiscal knowledge and guidance could bring meaningful worth and outlook to Assertio's operations.
$Assertio(ASRT.US$ mised to hit $2.50 40% down here
Read more